DoD Gulf War Illness, Idea Award | W81XWH 20 GWIRP IA

Opportunity Information: Apply for W81XWH 20 GWIRP IA

The Department of Defense Gulf War Illness Research Program (GWIRP) FY20 Idea Award (Funding Opportunity Number W81XWH-20-GWIRP-IA) is designed to jump-start bold, early-stage research ideas that could eventually lead to meaningful markers (biomarkers, molecular signatures, or other measurable indicators) or treatments for Gulf War Illness (GWI). It is explicitly positioned in the "Discovery" phase, meaning the program is looking for new directions and exploratory concepts rather than mature, late-stage validation projects. The main goal is to seed innovative, high-risk/high-reward work that can open up new avenues of investigation and ultimately improve clinical outcomes for Veterans affected by GWI from the 1990-1991 Gulf War.

A central theme of this award is innovation. Competitive applications are expected to bring genuinely creative thinking to GWI research, such as proposing a new scientific paradigm, challenging an established one, or reframing a long-standing problem using a fresh perspective. The announcement also notes that it can be considered innovative to adapt concepts from other symptom-based disorders that share overlapping features with GWI, including conditions like chronic fatigue syndrome or fibromyalgia. Multidisciplinary approaches are especially encouraged, reflecting the reality that GWI involves complex, multi-system symptoms that often do not fit neatly into a single field or organ system.

Unlike many grant mechanisms, preliminary data are not required for this Idea Award. The intention is to lower barriers for early concepts that have strong potential but may not yet have extensive supporting datasets. If applicants choose to include unpublished preliminary results, those data must come from the Principal Investigator (PI) or members of the research team. Even without preliminary data, proposals are still expected to rest on a solid scientific rationale built through logical reasoning and careful engagement with the existing literature, showing that the idea is grounded even if it is exploratory.

Impact is another major review driver. Applicants must clearly explain how the anticipated results could lead to a clinical impact for Veterans with GWI, even if that impact is not immediate within the project period. The focus must remain on GWI features and on Veterans of the 1990-1991 Gulf War who are affected by GWI; in other words, the work cannot drift into a general study of fatigue, pain, or other symptoms without directly tying the research questions back to Gulf War Illness and its Veteran population. The application is expected to state plainly what difference the project could make for GWI, whether through identifying mechanisms, defining subgroups, pointing to treatment targets, or laying groundwork for future therapeutic development.

The FY20 Idea Award highlights several areas of emphasis where the program has special interest, though applicants are not limited to these topics. Priority themes include innovative treatments for GWI and identifying causes and treatment targets tied to dysregulated biological systems. The announcement specifically calls attention to a wide symptom and system range, including cognitive difficulties (such as memory deficits and mood/behavior disturbances), non-restorative sleep and sleep disruption, chronic widespread pain, chronic debilitating fatigue, gastrointestinal issues (including dietary intolerances, GERD, and functional GI disorders), sinus and respiratory effects, headaches, dermatological problems, neurological dysfunction (central, peripheral, autonomic, and neuromuscular), immune dysfunction, and endocrine/exocrine/excretory dysfunction with particular attention to kidney and liver issues (including possible cytochrome P450 abnormalities). It also encourages work on microbiome variants, how stressors like exertion or immune challenges alter symptom severity and duration, and "disordered system crosstalk" where dysfunction in one system drives problems in another (for example, immune disruptions affecting the nervous system, or autonomic dysfunction affecting GI function).

In addition to symptom and systems biology, the award is interested in studies that identify molecular signatures underlying symptoms and that group symptom sets based on shared underlying biology. This includes genomic, proteomic, metabolomic, and epigenetic signatures that could help define subtypes of GWI or clarify mechanisms. The program also welcomes investigation into comorbidities, mortality, and differences by sex or ethnicity, reflecting a broader interest in understanding variability in GWI presentation and outcomes.

A notable optional feature is the Biorepository Contribution Option, tied to the Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI. This infrastructure exists to retain and distribute Gulf War Veteran biospecimens and related data for GWI research. Applicants are encouraged to contribute specimens and data to this repository, and projects that qualify for this option may request a slightly higher direct cost cap. The inclusion of this option signals the program's interest in building shared resources that can accelerate progress across the field, not just within single projects.

Funding is relatively small and targeted, consistent with the early-stage "idea" purpose. Direct costs for the entire period of performance are capped at $150,000, or up to $170,000 if applying under the Biorepository Contribution Option (with additional requirements referenced in the full announcement and associated attachments). The DoD planned to commit about $720,000 total to fund approximately three awards, with actual funding dependent on federal appropriations, application volume, and the outcomes of scientific and programmatic review. Awards were expected to be issued no later than September 30, 2021, and FY20 funds associated with these awards were anticipated to remain available for use only through September 30, 2026, consistent with federal fund expiration rules.

The opportunity is open in terms of applicant type (listed as unrestricted eligibility, subject to any additional clarifications in the full notice) and is administered by the Department of Defense, Department of the Army, through USAMRAA under CFDA 12.420. The funding instrument is listed as either a cooperative agreement or a grant, which typically means awardees should be prepared for standard federal oversight and reporting, and in the case of cooperative agreements, potentially more programmatic involvement by the funding agency than a standard grant.

Finally, the announcement clearly states what the Idea Award will not support. It does not fund studies that treat psychiatric disease or psychological stress as the primary cause of GWI, and it does not support ALS-focused research (although Gulf War Veterans with ALS can be included if ALS is part of the study's GWI case definition and the focus remains on GWI symptomatology). It also does not support clinical trials as defined by prospective assignment of human subjects to interventions to measure outcomes; investigators aiming to run trials are directed instead to separate GWIRP mechanisms like the Clinical Evaluation Award or the Therapeutic/Biomarker Trial Award. Overall, the Idea Award is best understood as seed funding for creative, biologically grounded, Veteran-relevant discovery research that can set up the next wave of diagnostics and treatments for Gulf War Illness.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Idea Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 24, 2020.
• Applicants must submit their applications by Sep 10, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 GWIRP IA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: